28 October 2021

DeepVerge PLC

("DeepVerge" or "Company")

Microtox^® PD installations to be part of a
Government National COVID Infrastructure Trial

Modern Water, a division of DeepVerge (AIM: DVRG), announces it has been selected to contribute newly enhanced monitoring equipment, with a  value of £0.48 million (including monitoring and consultancy fees) to be installed in a Government National COVID-19 Infrastructure Trial. The multiplex wastewater development trial is expected to last until the end of February 2022 and it is anticipated that revenue from these installations, on successful completion of the trial, will crystalize in the 2022 financial year.

Pandemic Response Equipment

The multiple unit installation consists of six upgraded Microtox^® toxicity monitoring and new models of the Microtox^® PD range for SARS-CoV-2 and other pathogen monitoring. In addition, software, data management capability, dashboards, encryption, and new AI models are fully integrated.

Gerry Brandon, CEO of DeepVerge plc, commented:

"Modern Water has been working on this project since March and we are delighted to finally have the Microtox^® PD form part of a national government covid infrastructural trial for a long-term early-warning solution offering automated real-time and remote monitoring of COVID in wastewater detection.

"We continue to see a rise in interest in our real-time wastewater monitoring solutions from several governments and these installations follow on from last week's announcement of £2.2m of Microtox^® PD shipments. With a growing recognition of the importance of wastewater, as well as our expertise, great science and cross-group teamwork from Modern Water, Labskin and Rinocloud, DeepVerge is well-placed to capitalise on current and future opportunities to work with governments, industries bodies and private companies to create a co-ordinated solution, not only to the current global pandemic but also future health challenges."

Enquiries:

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins. Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin microbiome for most of the top 20 global cosmetic company clients and remotely detect and identify in real-time, dangerous pathogens in wastewater treatment plants, drinking water, rivers, lakes and reservoirs.

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.